Clinical Trials Browser

Recurrence × Lenalidomide × 1 year × Clear all

NCT05283720 2026-04-13

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06149286 2026-04-13

OLYMPIA-5

Phase 3 Recruiting

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT05888493 2026-03-24

LEDA

Phase 3 Active not recruiting

Lymphoma, Follicular, Recurrence

NCT06313996 2026-03-18

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Phase 3 Withdrawn

Lymphoma, Follicular, Recurrence

NCT01615029 2026-03-16

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

Phase 1/2 Completed

45 enrolled 14 charts

Multiple Myeloma, Recurrence

NCT07460362 2026-03-10

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

Phase 2 Recruiting

Recurrence, Lymphoma, Mantle-Cell

NCT03601078 2026-03-04

KarMMa-2

Phase 2 Completed

Multiple Myeloma, Recurrence

NCT04712097 2026-02-04

Celestimo

Phase 3 Active not recruiting

Lymphoma, Follicular, Recurrence

NCT01562405 2026-01-14

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT02390869 2025-12-02

FIL_RENOIR12

Phase 3 Active not recruiting

Lymphoma, Follicular, Recurrence

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07018050 2025-09-22

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT05626322 2025-09-05

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 1/2 Terminated

6 enrolled 17 charts

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07126236 2025-08-17

REPIFIR

Phase 2 Recruiting

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06163040 2025-07-31

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Multiple Myeloma, Recurrence

NCT06651853 2025-07-23

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

Phase 2 Recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06414148 2025-06-05

EpLCART

Phase 2 Recruiting

Lymphoma, Recurrence, Neoplasm, Residual